EUVIMEDEUVIMED entdecken
Open Access

Clinical Utility of Cytological Methylation Assay in Cervical Cancer Screening Across Various Cervical Transformation Zones

Xiaoying Zhong iD, Xitong Jin iD, Yanan Cheng iD, Xiaopei Chao iD, Linghua Kong iD, Jing Wang iD, Pei Liu iD, Yuligh Liou iD, Demei Xin, Jinghe Lang iD, Lei Li iD

International Journal of Cancer · 15.10.2026 · 159 (8) · 2084-2096

DOI: 10.1002/ijc.70591 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 11.06.2026. Verfasst von Xiaoying Zhong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, DNA Methylation, Uterine Cervical Dysplasia, Early Detection of Cancer. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Independent Research Fund of State Key Laboratory of Complex, Severe and Rare Diseases in Peking Union Medical College Hospital, Key Research Project of Beijing Natural Science Foundation, CAMS Innovation Fund for Medical Sciences (CIFMS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type I to III cervical transformation zones (TZ‐1 to TZ‐3) may have various effects on cervical cancer screening and diagnostic outcomes. This study aims to evaluate the clinical utility of the cytological PAX1 / JAM3 methylation (CISCER) assay in cervical cancer screening, especially in TZ‐3 women. Between November 2020 and October 2022, 1782 women referred for colposcopy underwent liquid‐based cytology (LBC), high‐risk human papillomavirus (hrHPV) genotyping, and CISCER testing. After applying inclusion criteria, 1398 women were analyzed, including 1190 with documented TZ classification. Diagnostic performance for detecting cervical intraepithelial neoplasia grade 3 or worse (CIN3+) was compared across TZ subgroups. For CIN3+ detection, CISCER showed sensitivities of 67.4%, 72.0%, 48.3%, and 81.5% and specificities of 91.0%, 94.2%, 91.3%, and 89.8% in all women, TZ‐1, TZ‐2, and TZ‐3, respectively. Compared with LBC ≥ ASC‐US, hrHPV positivity, or HPV16/18 positivity, CISCER achieved the highest diagnostic accuracy, with AUC values of 0.792, 0.831, 0.698, and 0.856 across the respective groups. In both the overall cohort and TZ‐3 subgroup, CISCER positivity was associated with the highest CIN3+ risk (34.6% and 31.4%) and required the fewest colposcopy referrals per CIN3+ detected (2.9 and 3.2). Combining hrHPV testing with CISCER further improved risk stratification. CISCER demonstrated superior diagnostic performance across TZ types, particularly in TZ‐3, enabling improved CIN3+ risk discrimination while substantially reducing unnecessary colposcopy referrals compared with conventional cytology and HPV genotyping.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsDNA MethylationUterine Cervical DysplasiaEarly Detection of CancerHumansFemaleAdultPapillomavirus InfectionsMiddle AgedColposcopyCytodiagnosisPapillomaviridaeCervix UteriPaired Box Transcription Factors

Stichwörter der Autor:innen

DNA methylationcervical cancer screeningcervical transformation zone (TZ)hrHPV genotypingliquid‐based cytology (LBC)

Substanzen

PAX1 transcription factorPaired Box Transcription Factors

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.
  • National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China.
  • State Key Laboratory for Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China.
  • Department of Pathology, Peking Union Medical College Hospital, Beijing, China.
  • Department of Medical Laboratory, Beijing Origin-Poly Bio-Tec Co. Ltd., Beijing, China.
  • Department of Obstetrics and Gynecology, Beijing Tsinghua Changgung Hospital, Beijing, China.

ORCID-Profile: Xiaoying Zhong, Xitong Jin, Yanan Cheng, Xiaopei Chao, Linghua Kong, Jing Wang, Pei Liu, Yuligh Liou, Jinghe Lang, Lei Li

Förderung

  • Independent Research Fund of State Key Laboratory of Complex, Severe and Rare Diseases in Peking Union Medical College Hospital
  • Key Research Project of Beijing Natural Science Foundation
  • CAMS Innovation Fund for Medical Sciences (CIFMS)
  • National High Level Hospital Clinical Research Funding
  • Peking Union Medical College Hospital Talent Cultivation Program (Category D)
  • National Key Clinical Specialty Construction Project
  • Beijing Key Clinical Specialty Project (Beijing Chuiyangliu Hospital 2025)

Zitieren

APA

Zhong, X., Jin, X., Cheng, Y., Chao, X., Kong, L., Wang, J., Liu, P., Liou, Y., Xin, D., Lang, J., & Li, L. (2026). Clinical Utility of Cytological Methylation Assay in Cervical Cancer Screening Across Various Cervical Transformation Zones. International Journal of Cancer, 159(8), 2084-2096. https://doi.org/10.1002/ijc.70591

Vancouver

Zhong X, Jin X, Cheng Y, Chao X, Kong L, Wang J, et al. Clinical Utility of Cytological Methylation Assay in Cervical Cancer Screening Across Various Cervical Transformation Zones. International Journal of Cancer. 2026;159(8):2084-2096. doi:10.1002/ijc.70591

BibTeX
@article{Zhong2026,
  author = {Zhong, Xiaoying and Jin, Xitong and Cheng, Yanan and Chao, Xiaopei and Kong, Linghua and Wang, Jing and Liu, Pei and Liou, Yuligh and Xin, Demei and Lang, Jinghe and Li, Lei},
  title = {Clinical Utility of Cytological Methylation Assay in Cervical Cancer Screening Across Various Cervical Transformation Zones},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {8},
  pages = {2084--2096},
  doi = {10.1002/ijc.70591}
}
Kostenlos starten →